Kane Biotech Inc. (TSXV: KNE)
Health Care · Biotechnology · CA
CA$0.03
-16.67% today · -29.4% 1Y
Kane Biotech Inc. (TSXV: KNE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.47M and employs 32 people.
Over the last twelve months the share price has lost 29.4%, trading between 0.02 and 0.05.
Tweenvest scores Kane Biotech Inc. across four factors: quality 3/100, value 32/100, growth 0/100. Its strongest factor is value.
KNE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.47M
- Revenue (TTM)
- $41.96K
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.31
- 52-week high
- CA$0.05
- 52-week low
- CA$0.02
- Avg volume (3M)
- —
- Shares outstanding
- 205.21M
- Employees
- 32
- Next earnings
- —
About Kane Biotech Inc.
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.
- ISIN
- CA4838092084
- Founded
- 2001
- Listed since
- Oct 1, 2003
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.